Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2017 - Product Image

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2017

  • ID: 4330533
  • Report
  • Region: Global
  • 68 Pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aduro BioTech Inc
  • Bolder Biotechnology Inc
  • Genzyme Corp
  • Johnson & Johnson
  • Pharmaxis Ltd
  • Savara Inc
  • MORE
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2017

Summary:

According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H2 2017'; Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production, differentiation, and function of granulocytes and macrophages.

The report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H2 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 4, 1 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Respiratory, Toxicology, Central Nervous System, Dermatology, Gastrointestinal and Infectious Disease which include indications Prostate Cancer, Colorectal Cancer, Lung Disease, Melanoma, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Respiratory Distress Syndrome, Alzheimer's Disease, Appendicitis, Asthma, Chemotherapy Induced Neutropenia, Chronic Obstructive Pulmonary Disease (COPD), Crohn's Disease (Regional Enteritis), Lung Infections, Lung Injury, Malignant Pleural Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Mild Cognitive Impairment, Neurology, Ovarian Cancer, Parkinson's Disease, Peritonitis, Radiation Induced Myelosuppression, Radiation Injury, Respiratory Syncytial Virus (RSV) Infections, Skin Ulcers and Wounds.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
  • The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aduro BioTech Inc
  • Bolder Biotechnology Inc
  • Genzyme Corp
  • Johnson & Johnson
  • Pharmaxis Ltd
  • Savara Inc
  • MORE
Introduction

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Overview

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development

Aduro BioTech Inc

Bolder Biotechnology Inc

Genzyme Corp

Johnson & Johnson

OncBioMune Pharmaceuticals Inc

Pharmaxis Ltd

Savara Inc

Targovax ASA

XL-protein GmbH

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Drug Profiles

BBT-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GVAX Colorectal Cancer Vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONCOS-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prostatac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-2200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for RSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Discontinued Products

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Product Development Milestones

Featured News & Press Releases

Jun 27, 2017: Enrollment to Begin in OncBioMunes Trial of ProscaVax for Prostate Cancer in Mexico

Jun 21, 2017: OncBioMune Receives Patent Protecting Novel Cancer Vaccine in Mexico

Jun 20, 2017: OncBioMune Awarded Patent for ProscaVax in Japan

Jun 07, 2017: OncBioMune Protects ProscaVax Cancer Treatment Technology in Hong Kong

Jun 01, 2017: Protocol Submitted to FDA for Phase 2 Clinical Trial of ProscaVax as Immunotherapy for Early-Stage Prostate Cancer

May 10, 2017: Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study

May 10, 2017: Savara Announces Expedited U.S. Molgradex Development Strategy

May 03, 2017: OncBioMune Completes Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer

Feb 02, 2017: OncBioMune Announces Presentation on ProscaVax at the 2017 American Association for Cancer Research Meeting

Jan 26, 2017: Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials

Jan 18, 2017: Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico

Jan 10, 2017: OncBioMune Submitting Clinical Trial of World's First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute

Dec 28, 2016: Patients Pre-Screened for OncBioMune Pharmaceuticals Phase 2/3 Trial of ProscaVax for Prostate Cancer

Dec 12, 2016: OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology

Dec 08, 2016: OncBioMune and the Clinical Trial Investigators Have Agreed Upon the Protocol for Their Phase 2 Trial of Novel Vaccine for Early Stage Prostate Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indications, H2

Number of Products under Development by Indications, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Aduro BioTech Inc, H2

Pipeline by Bolder Biotechnology Inc, H2

Pipeline by Genzyme Corp, H2

Pipeline by Johnson & Johnson, H2

Pipeline by OncBioMune Pharmaceuticals Inc, H2

Pipeline by Pharmaxis Ltd, H2

Pipeline by Savara Inc, H2

Pipeline by Targovax ASA, H2

Pipeline by XL-protein GmbH, H2

Dormant Products, H2

Dormant Products, H2 2017 (Contd..1), H2

Discontinued Products, H2

List of Figures:

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Top 10 Routes of Administration, H2

Number of Products by Stage and Top 10 Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aduro BioTech Inc
  • Bolder Biotechnology Inc
  • Genzyme Corp
  • Johnson & Johnson
  • OncBioMune Pharmaceuticals Inc
  • Pharmaxis Ltd
  • Savara Inc
  • Targovax ASA
  • XL-protein GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll